
James J. Harding, MD
Gastrointestinal Oncologist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Gastrointestinal Cancers
- Liver Cancer (Hepatocellular Carcinoma)
- Bile Duct Cancers (Cholangiocarcinoma)
Request an Appointment
About Me
- Assistant Attending Physician
I am a board-certified medical oncologist who specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer, as well as other gastrointestinal cancers. My primary goal is to provide the best possible treatment and individualized care for people with these diseases. I work closely with a team of surgeons, radiation oncologists, and other medical professionals who specialize in the diagnosis and treatment of gastrointestinal cancer.
Read more
In my research, I am trying to find new, effective therapies for gastrointestinal cancer, particularly primary liver and bile duct tumors. For example, I am working on ways to use a patient’s own immune system to fight cancer, which is called immunotherapy. In addition, I am investigating strategies to block specific cellular pathways that cancer uses to grow. I have developed and am leading numerous national and international clinical trials of these new cancer therapies for patients with liver, bile duct cancers, and other solid tumors.
I am also focused on improving how we conduct clinical research with patients and increasing access to clinical trials. To this aim, I am a standing member of the Institutional Review Board, which is the committee that approves all clinical research at Memorial Sloan Kettering. I am also part of several other executive committees aimed at improving the conduct of clinical trials.
My research and training has been supported by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the National Institutes of Health, the American Association for Cancer Research, and the Howard Hughes Medical Institute. My work has been published in the New England Journal of Medicine, Nature, Nature Medicine, the Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research, and Cancer.
A gastrointestinal (GAS-troh-EN-teh-RAH-loh-jist) oncologist is a cancer doctor with special training in the gastrointestinal (GI) system. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers, as well as GI stromal tumors and neuroendocrine tumors.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Gastrointestinal Cancers
- Liver Cancer (Hepatocellular Carcinoma)
- Bile Duct Cancers (Cholangiocarcinoma)
- Gallbladder Cancers
- Fibrolamellar Carcinoma
- Early Drug Development
- Immunotherapy
Education
- MD, Albert Einstein College of Medicine
Residencies
- Internal Medicine - NewYork-Presbyterian Hospital
Fellowships
- Oncology/Hematology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment

New Patients
Current Patients
Contact and Location
Dr. Harding sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Harding
- A Phase 1 Study of KIN-3248 in People With Solid Tumors
- A Phase 1/2 Study of Relatlimab in Combination with Nivolumab and Bevacizumab for People with Advanced Liver Cancer
- A Phase 2 Study of BI 907828 in People With Biliary Tract Cancer, Pancreatic Cancer, and Other Solid Tumors
- Clinical Trials Co-Investigated by Dr. Harding
- A Phase 1a Study of LOXO-435 in People with Advanced Solid Tumors Containing FGFR3 Gene Changes
Read more
- A Phase I Study of AGEN1811 and Balstilimab Immunotherapy in People with Fibrolamellar Carcinoma or Another Type of Gastrointestinal Cancer
- A Phase I Study of AZD1390 plus Radiation Therapy in Patients with Glioblastoma Multiforme or Brain Metastases
- A Phase I Study of RLY-4008 for Intrahepatic Cholangiocarcinoma and Other Advanced Solid Tumors

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Harding’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James J. Harding discloses the following relationships and financial interests:
-
Bristol-Myers Squibb
Professional Services and Activities -
COR2ED GmbH
Professional Services and Activities -
Creative Educational Concepts, Inc.
Professional Services and Activities -
Elevar Therapeutics
Professional Services and Activities -
Exelixis
Professional Services and Activities -
Hepion Pharmaceuticals, Inc.
Professional Services and Activities
-
MJH Life Sciences
Professional Services and Activities -
Medivir AB
Professional Services and Activities -
Merck & Co Inc.
Professional Services and Activities -
National Comprehensive Cancer Network
Professional Services and Activities -
Tempus Labs, Inc.
Professional Services and Activities -
Zymeworks Inc.
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].